Alto Neuroscience, Inc. (ANRO)
(Delayed Data from NYSE)
$11.17 USD
-0.27 (-2.36%)
Updated Oct 1, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Alto Neuroscience, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -36.31 | -27.71 | -9.19 | NA | NA |
Depreciation/Amortization & Depletion | 0.37 | 0.34 | 0.15 | NA | NA |
Net Change from Assets/Liabilities | -0.70 | 4.58 | -0.57 | NA | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | NA | NA |
Other Operating Activities | 3.18 | 2.40 | 0.35 | NA | NA |
Net Cash From Operating Activities | -33.45 | -20.39 | -9.26 | NA | NA |
Property & Equipment | -0.47 | -0.73 | -0.68 | NA | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | NA | NA |
Investments | 0.00 | 0.00 | 0.00 | NA | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | NA | NA |
Net Cash from Investing Activities | -0.47 | -0.73 | -0.68 | NA | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 70.18 | 34.31 | 31.89 | NA | NA |
Issuance (Repayment) of Debt | 0.00 | 9.83 | 0.00 | NA | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | NA | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | NA | NA |
Other Financing Activities | -2.05 | -0.34 | -0.21 | NA | NA |
Net Cash from Financing Activities | 68.13 | 43.79 | 31.69 | NA | NA |
Effect of Exchange Rate Changes | -0.01 | -0.02 | -0.05 | NA | NA |
Net Change In Cash & Equivalents | 34.20 | 22.64 | 21.70 | NA | NA |
Cash at Beginning of Period | 48.34 | 25.71 | 4.01 | NA | NA |
Cash at End of Period | 82.55 | 48.34 | 25.71 | NA | NA |
Diluted Net EPS | -9.73 | -8.04 | NA | NA | NA |
Fiscal Year End for Alto Neuroscience, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -29.45 | -13.42 | -36.31 | NA | -15.95 |
Depreciation/Amortization & Depletion | 0.21 | 0.10 | 0.37 | NA | 0.20 |
Net Change from Assets/Liabilities | 1.18 | -0.26 | -0.70 | NA | -0.38 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Other Operating Activities | 5.39 | 2.59 | 3.18 | NA | 1.97 |
Net Cash From Operating Activities | -22.68 | -10.98 | -33.45 | NA | -14.16 |
Property & Equipment | -0.56 | -0.22 | -0.47 | NA | -0.08 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Net Cash from Investing Activities | -0.56 | -0.22 | -0.47 | NA | -0.08 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 137.65 | 137.59 | 70.18 | NA | 25.04 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Other Financing Activities | -3.33 | -3.03 | -2.05 | NA | -0.09 |
Net Cash from Financing Activities | 134.33 | 134.56 | 68.13 | NA | 24.95 |
Effect of Exchange Rate Changes | -0.01 | -0.01 | -0.01 | NA | -0.03 |
Net Change In Cash & Equivalents | 111.07 | 123.35 | 34.20 | NA | 10.69 |
Cash at Beginning of Period | 82.55 | 82.55 | 48.34 | NA | 48.34 |
Cash at End of Period | 193.62 | 205.90 | 82.55 | NA | 59.03 |
Diluted Net EPS | -0.60 | -0.76 | NA | NA | NA |